Polymer–drug conjugates for novel molecular targets

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Duncan R: The dawning era of polymer therapeutics. Nat. Rev. Drug Discov.2(5),347–360 (2003).▪▪ Landmark paper defining the polymer therapeutics field.
  Medline CASGoogle Scholar
• 2  Haag R, Kratz F: Polymer therapeutics: Concepts and applications. Angew. Chem. Int. Ed.45(8),1198–1215 (2006).
  Medline CASGoogle Scholar
• 3  Duncan R: Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer6(9),688–701 (2006).
  Medline CASGoogle Scholar
• 4  Li C, Wallace S: Polymer–drug conjugates: recent development in clinical oncology. Adv. Drug Deliv. Rev.60(8),886–898 (2008).
  Medline CASGoogle Scholar
• 5  Vicent MJ, Duncan R: Polymer therapeutics: clinical applications and challenges for development. Adv. Drug Deliv. Rev.61(13),1117–1232 (2009).
  Medline CASGoogle Scholar
• 6  Ringsdorf H: Structure and properties of pharmacologically active polymers. J. Polym. Sci. C-Polym. Symp.51,135–153 (1975).
  CASGoogle Scholar
• 7  Meerum Terwogt JM, Ten Bokkel Huinink WW, Schellens JH et al.: Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs12(4),315–323 (2001).
  Medline CASGoogle Scholar
• 8  Vasey PA, Kaye SB, Morrison R et al.: Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents – drug–polymer conjugates. Clin. Cancer Res.5(1),83–94 (1999).▪▪ First paper describing a polymer–drug conjugate that reached the clinical trials.
  Medline CASGoogle Scholar
• 9  Yurkovetskiy AV, Fram RJ: XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer. Adv. Drug Deliv. Rev.61(13),1193–1202 (2009).
  Medline CASGoogle Scholar
• 10  Brocchini S, Duncan R: Polymer–drug conjugates: drug release from pendent linkers. In: Encyclopaedia of controlled release. Mathiowitz E (Ed.). Wiley, NY, USA 786–816 (1999).
  Google Scholar
• 11  Duncan R, Cable HC, Lloyd JB, Rejmanova P, Kopecek J: Polymers containing enzymatically degradable bonds .7. Design of oligopeptide side-chains in poly[N-(2-hydroxypropyl)methacrylamide] co-polymers to promote efficient degradation by lysosomal-enzymes. Makromol. Chem.Macromol. Chem. Phys.184(10),1997–2008 (1983).
  CASGoogle Scholar
• 12  Allen TM: Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer2(10),750–763 (2002).
  Medline CASGoogle Scholar
• 13  Brumlik MJ, Daniel BJ, Waehler R, Curiel DT, Giles FJ, Curiel TJ: Trends in immunoconjugate and ligand–receptor based targeting development for cancer therapy. Expert Opin. Drug Deliv.5(1),87–103 (2008).
  Medline CASGoogle Scholar
• 14  Seymour LW, Ferry DR, Anderson D et al.: Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol.20(6),1668–1676 (2002).
  Medline CASGoogle Scholar
• 15  Matsumura Y, Maeda H: A new concept for macromolecular therapeutics in cancer-chemotherapy – mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res.46(12),6387–6392 (1986).
  Medline CASGoogle Scholar
• 16  Iyer AK, Khaled G, Fang J, Maeda H: Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today11(17–18),812–818 (2006).
  Medline CASGoogle Scholar
• 17  Vicent MJ, Duncan R: Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol.24(1),39–47 (2006).
  Medline CASGoogle Scholar
• 18  Vicent MJ, Ringsdorf H, Duncan R: Polymer therapeutics: clinical applications and challenges for development. Adv. Drug Deliv. Rev.61(13),1117–1120 (2009).
  Medline CASGoogle Scholar
• 19  Chipman SD, Oldham FB, Pezzoni G, Singer JW: Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer–drug conjugate. Int. J. Nanomed.1(4),375–383 (2006).
  Medline CASGoogle Scholar
• 20  Seymour LW, Ferry DR, Kerr DJ et al.: Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int. J. Oncol.34(6),1629–1636 (2009).
  Medline CASGoogle Scholar
• 21  Danhauserriedl S, Hausmann E, Schick HD et al.: Phase-I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest. New Drugs11(2–3),187–195 (1993).
  Medline CASGoogle Scholar
• 22  Springett GM, Takimoto C, McNamara M et al.: Phase I study of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies. J. Clin. Oncol.22(14),3127 (2004).
  Google Scholar
• 23  Schluep T, Hwang J, Cheng JJ et al.: Preclinical efficacy of the camptothecin–polymer conjugate IT-101 in multiple cancer models. Clin. Cancer Res.12(5),1606–1614 (2006).
  Medline CASGoogle Scholar
• 24  Bissett D, Cassidy J, de Bono JS et al.: Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). Brit. J. Cancer91(1),50–55 (2004).
  Medline CASGoogle Scholar
• 25  Soepenberg O, de Jonge MJA, Sparreboom A et al.: Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. Clin. Cancer Res.11(2),703–711 (2005).
  Medline CASGoogle Scholar
• 26  Davis ME: Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. Adv. Drug Deliv. Rev.61(13),1189–1192 (2009).
  Medline CASGoogle Scholar
• 27  Li C, Yu DF, Newman RA et al.: Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid) paclitaxel conjugate. Cancer Res.58(11),2404–2409 (1998).
  Medline CASGoogle Scholar
• 28  Singer JW, Shaffer S, Baker B et al.: Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane. Anticancer Drugs16(3),243–254 (2005).
  Medline CASGoogle Scholar
• 29  Shaffer SA, Baker Lee C, Kumar A, Singer JW: Proteolysis of XYOTAX by lysosomal cathepsin B; metabolic profiling in tumor cells using LC-MS. Eur. J. Cancer38,428 (2002).
  Google Scholar
• 30  Rademaker-Lakhai JM, Terret C, Howell SB et al.: A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin. Cancer Res.10(10),3386–3395 (2004).
  Medline CASGoogle Scholar
• 31  Nowotnik DP, Cvitkovic E: ProLindac™ (AP5346): a review of the development of an HPMA DACH platinum polymer therapeutic. Adv. Drug Deliv. Rev.61(13),1214–1219 (2009).
  Medline CASGoogle Scholar
• 32  Greco F, Vicent MJ: Polymer–drug conjugates: current status and future trends. Frontiers Biosci.13,2744–2756 (2008).
  Medline CASGoogle Scholar
• 33  Vicent MJ, Dieudonne L, Carbajo RJ, Pineda-Lucena A: Polymer conjugates as therapeutics: future trends, challenges and opportunities. Expert Opin. Drug Deliv.5(5),593–614 (2008).
  Medline CASGoogle Scholar
• 34  Gaspar R, Duncan R: Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv. Drug Deliv. Rev.61(13),1220–1232 (2009).
  Medline CASGoogle Scholar
• 35  Lammers T: Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations. Adv. Drug Deliv. Rev.62(2),203–230 (2010).
  Medline CASGoogle Scholar
• 36  Greco F, Vicent MJ: Combination therapy: Opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv. Drug Deliv. Rev.61(13),1203–1213 (2009).
  Medline CASGoogle Scholar
• 37  Satchi-Fainaro R, Duncan R, Barnes CM: Polymer therapeutics for cancer: current status and future challenges. Polymer Therapeutics II193,1–65 (2006).
  CASGoogle Scholar
• 38  Khandare J, Minko T: Polymer–drug conjugates: progress in polymeric prodrugs. Progr. Polym. Sci.31(4),359–397 (2006).
  CASGoogle Scholar
• 39  Lammers T, Ulbrich K: HPMA copolymers: 30 years of advances. Adv. Drug Deliv. Rev.62(2),119–121 (2009).
  MedlineGoogle Scholar
• 40  Hanahan D, Weinberg RA: The hallmarks of cancer. Cell100(1),57–70 (2000).
  Medline CASGoogle Scholar
• 41  Gerber HP, McMurtrey A, Kowalski J et al.: Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3´-kinase Akt signal transduction pathway – requirement for Flk-1/KDR activation. J. Biol. Chem.273(46),30336–30343 (1998).
  Medline CASGoogle Scholar
• 42  Arcaro A, Wymann MP: Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor – the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem. J.296,297–301 (1993).
  Medline CASGoogle Scholar
• 43  Vlahos CJ, Matter WF, Hui KY, Brown RF: A specific inhibitor of phosphatidylnositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one (Ly294002). J. Biol. Chem.269(7),5241–5248 (1994).
  Medline CASGoogle Scholar
• 44  Varticovski L, Lu ZR, Mitchell K, de Aos I, Kopecek J: Water-soluble HPMA copolymer-wortmannin conjugate retains phosphoinositide 3-kinase inhibitory activity in vitro and in vivo. J. Control. Rel.74(1–3),275–281 (2001).
  Medline CASGoogle Scholar
• 45  Bae Y, Diezi TA, Zhao A, Kwon GS: Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents. J. Control. Rel.122,324–330 (2007).
  Medline CASGoogle Scholar
• 46  Takabe K, Paugh SW, Milstien S, Spiegel S: ‘Inside-out’ signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol. Rev.60(2),181–195 (2008).
  Medline CASGoogle Scholar
• 47  Avery K, Avery S, Shepherd J, Heath PR, Moore H: Sphingosine-1-phosphate mediates transcriptional regulation of key targets associated with survival, proliferation, and pluripotency in human embryonic stem cells. Stem Cells Dev.17(6),1195–1205 (2008).
  Medline CASGoogle Scholar
• 48  Huwiler A, Pfeischifter J: New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets. Biochem. Pharmacol.75(10),1893–1900 (2008).
  Medline CASGoogle Scholar
• 49  Ghosh SC, Auzenne E, Khodadadian M, Farquhar D, Klostergaard J: N,N-dimethylsphingosine conjugates of poly-L-glutamic acid: synthesis, characterization, and initial biological evaluation. Bioorg. Med. Chem. Lett.19(3),1012–1017 (2009).
  Medline CASGoogle Scholar
• 50  Richter K, Buchner J: HSP90: chaperoning signal transduction. J. Cell. Physiol.188(3),281–290 (2001).
  Medline CASGoogle Scholar
• 51  Blagosklonny MV: HSP-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia16(4),455–462 (2002).
  Medline CASGoogle Scholar
• 52  Borgman MP, Ray A, Kolhatkar RB, Sausville EA, Burger AM, Ghandehari H: Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy. Pharm. Res.26(6),1407–1418 (2009).▪ Geldanamycin, an HSP-90 inhibitor, was conjugated designing a N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer–AHGDM-RDGfK. The conjugate showed greater activity and reduced toxicity than the free drug for treatment of prostate cancer.
  Medline CASGoogle Scholar
• 53  Bae Y, Buresh RA, Williamson TP, Chen TH, Furgeson DY: Intelligent biosynthetic nanobiomaterials for hyperthermic combination chemotherapy and thermal drug targeting of HSP90 inhibitor geldanamycin. J. Control. Rel.122(1),16–23 (2007).
  Medline CASGoogle Scholar
• 54  Alam JJ: Apoptosis: target for novel drugs. Trends Biotechnol.21(11),479–483 (2003).
  Medline CASGoogle Scholar
• 55  Reed JC: Apoptosis-based therapies. Nat. Rev. Drug Discov.1(2),111–121 (2002).
  Medline CASGoogle Scholar
• 56  Green DR: Apoptotic pathways: ten minutes to dead. Cell121(5),671–674 (2005).
  Medline CASGoogle Scholar
• 57  Vicent MJ: Polymer–drug conjugates as modulators of cellular apoptosis. AAPS J.9(2),E200–207 (2007).
  MedlineGoogle Scholar
• 58  Sharma RA, Gescher AJ, Steward WP: Curcumin: the story so far. Eur. J. Cancer41(13),1955–1968 (2005).
  Medline CASGoogle Scholar
• 59  Li J, Wang Y, Yang C et al.: PEGylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1. Mol. Pharmacol.76(1),81–90 (2009).▪ Curcumin, a Jab1 inhibitor with poor solubility, was PEGylated showing antiproliferative activity higher than the free drug.
  Medline CASGoogle Scholar
• 60  Juin P, Geneste O, Raimbaud E, Hickman JA: Shooting at survivors: Bcl-2 family members as drug targets for cancer. Biochim. Biophys. Acta1644(2–3),251–260 (2004).
  Medline CASGoogle Scholar
• 61  Oman M, Liu JH, Chen J et al.: Using N-(2-hydroxypropyl) methacrylamide copolymer drug bioconjugate as a novel approach to deliver a Bcl-2-targeting compound HA14–1 in vivo. Gen. Ther. Mol. Biol.10A,113–122 (2006).
  Google Scholar
• 62  Greco F, Vicent MJ, Penning NA, Nicholson RI, Duncan R: HPMA copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines. J. Drug Target.13(8–9),459–470 (2005).
  Medline CASGoogle Scholar
• 63  Vicent MJ, Greco F, Nicholson RI, Paul A, Griffiths PC, Duncan R: Polymer therapeutics designed for a combination therapy of hormone-dependent cancer. Angew. Chem. Int. Ed.44(26),4061–4066 (2005).▪▪ HPMA–doxorubicin–aminoglutethimide conjugate represents the first polymer-based combination therapy in this case as treatment for hormone-dependent breast cancer.
  Medline CASGoogle Scholar
• 64  Greco F, Vicent MJ, Gee S et al.: Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells. J. Control. Rel.117(1),28–39 (2007).
  Medline CASGoogle Scholar
• 65  Lammers T, Subr V, Ulbrich K et al.: Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials30(20),3466–3475 (2009).
  Medline CASGoogle Scholar
• 66  Santucci L, Mencarelli A, Renga B et al.: Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO-PEGylated epirubicin. FASEB J.20(2),765–776 (2006).
  Medline CASGoogle Scholar
• 67  Santucci L, Mencarelli A, Renga B et al.: Cardiac safety and antiturnoral activity of a new nitric oxide derivative of PEGylated epirubicin in mice. Anti-Cancer Drugs18(9),1081–1091 (2007).
  Medline CASGoogle Scholar
• 68  Folkman J: Tumor angiogenesis: therapeutic implications. N. Engl. J. Med.285,1182–1186 (1971).
  Medline CASGoogle Scholar
• 69  Segal E, Satchi-Fainaro R: Design and development of polymer conjugates as anti-angiogenic agents. Adv. Drug Deliv. Rev.61(13),1159–1176 (2009).
  Medline CASGoogle Scholar
• 70  Kragh M, Spang-Thomsen M, Kristjansen PE: Time until initiation of tumor growth is an effective measure of the anti-angiogenic effect of TNP-470 on human glioblastoma in nude mice. Oncol. Rep.6(4),759–762 (1999).
  Medline CASGoogle Scholar
• 71  Satchi-Fainaro R, Puder M, Davies JW et al.: Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat. Med.10(3),255–261 (2004).▪▪ Key paper describing the first polymer antiangiogenic conjugate.
  Medline CASGoogle Scholar
• 72  Satchi-Fainaro R, Mamluk R, Wang L et al.: Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell7(3),251–261 (2005).
  Medline CASGoogle Scholar
• 73  Chesler L, Goldenberg DD, Seales IT et al.: Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res.67,9435–9442 (2007).
  Medline CASGoogle Scholar
• 74  Benny O, Fainaru O, Adini A et al.: An orally delivered small-molecule formulation with antiangiogenic and anticancer activity. Nat. Biotechnol.26(7),799–807 (2008).
  Medline CASGoogle Scholar
• 75  Segal E, Pan H, Ofek P et al.: Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS One4(4),e5233 (2009).
  MedlineGoogle Scholar
• 76  Browder T, Butterfield CE, Kraling BM et al.: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer. Res.60,1878–1886 (2000).
  Medline CASGoogle Scholar
• 77  Miller K, Erez R, Segal E, Shabat D, Satchi-Fainaro R: Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew. Chem. Int. Ed.48(16),2949–2954 (2009).
  Medline CASGoogle Scholar
• 78  Zhu G, Cao X, Chang JY, Milas L, Wallace S, Li C: Polymeric retinoid prodrug PG-4HPR enhances the radiation response of lung cancer. Oncol. Rep.18(3),645–651 (2007).
  Medline CASGoogle Scholar
• 79  Cuchelkar V, Kopeckova P, Kopecek J: Synthesis and biological evaluation of disulfide-linked HPMA copolymer-mesochlorin e6 conjugates. Macromol. Biosci.8(5),375–383 (2008).
  Medline CASGoogle Scholar
• 80  Lammers T, Peschke P, Kuhnlein R et al.: Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems. J. Control. Rel.117(3),333–341 (2007).
  Medline CASGoogle Scholar
• 81  Lammers T, Subr V, Peschke P et al.: Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy. Br. J. Cancer99(6),900–910 (2008).
  Medline CASGoogle Scholar
• 82  Bettio F, Canevari M, Marzano C et al.: Synthesis and biological in vitro evaluation of novel PEG-psoralen conjugates. Biomacromol.7(12),3534–3541 (2006).
  Medline CASGoogle Scholar
• 83  Tsujihara K, Hongu M, Saito K et al.: Na⁺-glucose cotransporter inhibitors as antidiabetics. 1. Synthesis and pharmacological properties of 4´-dehydroxyphlorizin derivatives based on a new concept. Chem. Pharm. Bull.44(6),1174–1180 (1996).
  Medline CASGoogle Scholar
• 84  Ikumi Y, Kida T, Sakuma S, Yamashita S, Akashi M: Polymer-phloridzin conjugates as an anti-diabetic drug that inhibits glucose absorption through the Na⁺/glucose cotransporter (SGLT1) in the small intestine. J. Control. Rel.125(1),42–49 (2008).▪ Poly-L-glutamic acid–phloridzin conjugate is a novel oral antidiabetic drug. The conjugate inhibits the increase in the blood glucose level (after oral administration of glucose in rats), comparing to the free drug.
  Medline CASGoogle Scholar
• 85  Sakuma S, Sagawa T, Masaoka Y et al.: Stabilization of enzyme-susceptible glucoside bonds of phloridzin through conjugation with poly(γ-glutamic acid). J. Control. Rel.133(2),125–131 (2009).
  Medline CASGoogle Scholar
• 86  Miyamoto Y, Akaike T, Yoshida M, Goto S, Horie H, Maeda H: Potentiation of nitric oxide-mediated vasorelaxation by xanthine oxidase inhibitors. Proc. Soc. Exp. Biol. Med.211(4),366–373 (1996).
  Medline CASGoogle Scholar
• 87  Fang J, Iyer AK, Seki T, Nakamura H, Greish K, Maeda H: SMA-copolymer conjugate of AHPP: a polymeric inhibitor of xanthine oxidase with potential antihypertensive effect. J. Control. Rel.135(3),211–217 (2009).▪ Conjugation of 4-amino-6-hydroxypyrazolo[3,4-d]pyrimidine to copoly(styrene-maleic acid) showed significantly antihypertensive effect with sustained in vivo activity, increasing amount of nitric oxide in vascular endothelial system, by inhibition of O2-.
  Medline CASGoogle Scholar
• 88  Flexner C: HIV-protease inhibitors. N. Engl. J. Med.338(18),1281–1292 (1998).
  Medline CASGoogle Scholar
• 89  Gunaseelan S, Debrah O, Wan L et al.: Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay. Bioconjug. Chem.15(6),1322–1333 (2004).
  Medline CASGoogle Scholar
• 90  Wan L, Zhang X, Gunaseelan S et al.: Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects. AIDS Res. Ther.3,12 (2006).
  MedlineGoogle Scholar
• 91  Gao Y, Katsuraya K, Kaneko Y, Mimura T, Nakashima H, Uryu T: Synthesis of Azidothymidine-bound sulfated alkyl oligosaccharides and their inhibitory effects on AIDS virus infection in vitro. Polym. J.30,243–248 (1998).
  CASGoogle Scholar
• 92  Vlieghe P, Clerc T, Pannecouque C et al.: Synthesis of new covalently bound κ-carrageenan-AZT conjugates. J. Med. Chem.45,1275–1283 (2002).
  Medline CASGoogle Scholar
• 93  Wannachaiyasit S, Chanvorachote P, Nimmannit U: A novel anti-HIV dextrin-zidovudine conjugate improving the pharmacokinetics of zidovudine in rats. AAPS Pharm. Sci. Tech.9(3),840–850 (2008).
  Medline CASGoogle Scholar
• 94  Giammona G, Cavallaro G, Pitarresi G: Studies of macromolecular prodrugs of zidovudine. Adv. Drug Deliv. Rev.39,153–164 (1999).
  Medline CASGoogle Scholar
• 95  Chimalakonda KC, Agarwal HK, Kumar A, Parang K, Mehvar R: Synthesis, analysis, in vitro characterization, and in vivo disposition of a lamivudine-dextran conjugate for selective antiviral delivery to the liver. Bioconjug. Chem.18(6),2097–2108 (2007).
  Medline CASGoogle Scholar
• 96  Heidemann HT, Gerkens JF, Jackson EK, Branch RA: Effect of aminophylline on renal vasoconstriction produced by amphotericin B in the rat. Naunyn Schmi. Arch. Pharmacol.324(2),148–152 (1983).
  CASGoogle Scholar
• 97  Cereghetti DM, Carreira EM: Amphotericin B: 50 years of chemistry and biochemistry. Synthesis-Stuttgart (6),914–942 (2006).
  Google Scholar
• 98  Trejo WH, Bennett RE: Streptomyces nodosus sp. n., the amphotericin-producing organism. J. Bacteriol.85,436–439 (1963).
  Medline CASGoogle Scholar
• 99  Sedlak M, Buchta V, Kubicova L, Simunek P, Holcapek M, Kasparova P: Synthesis and characterisation of a new amphotericin B-methoxypoly(ethylene glycol) conjugate. Bioorg. Med. Chem. Lett.11(21),2833–2835 (2001).
  Medline CASGoogle Scholar
• 100  Sedlak M, Pravda M, Staud F, Kubicova L, Tycova K, Ventura K: Synthesis of pH-sensitive amphotericin B-poly(ethylene glycol) conjugates and study of their controlled release in vitro. Bioorg. Med. Chem.15(12),4069–4076 (2007).
  Medline CASGoogle Scholar
• 101  Sedlak M, Drabina P, Bilkova E, Simunek P, Buchta V: New targeting system for antimycotic drugs: β-glucosidase sensitive amphotericin B-star poly(ethylene glycol) conjugate. Bioorg. Med. Chem. Lett.18(9),2952–2956 (2008).
  Medline CASGoogle Scholar
• 102  Chappuis F, Sundar S, Hailu A et al.: Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol.5(11),873–882 (2007).
  Medline CASGoogle Scholar
• 103  Mueller Y, Nguimfack A, Cavailler P et al.: Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda. Ann. Trop. Med. Parasitol.102(1),11–19 (2008).
  Medline CASGoogle Scholar
• 104  Golenser J, Frankerburg S, Erhenfreund T, Domb AJ: Efficacious treatment of experimental leishmaniasis with amphotericin B- arabinogalactan water-soluble derivatives Antimicrob. Agent Chemother.43 (9),2209–2214 (1999).
  MedlineGoogle Scholar
• 105  Nicoletti S, Seifert K, Gilbert IH: N-(2-hydroxypropyl)methacrylamide-amphotericin B (HPMA-AmB) copolymer conjugates as antileishmanial agents. Int. J. Antimicrob. Agents33(5),441–448 (2009).
  Medline CASGoogle Scholar
• 106  Chaudhuri G, Mukhopadhyay A, Basu SK: Selective delivery of drugs to macrophages through a highly specific receptor. An efficient chemotherapeutic approach against leishmaniasis. Biochem. Pharmacol.38,2995–3002 (1989).
  Medline CASGoogle Scholar
• 107  Nan A, Nanayakkara NP, Walker LA, Yardley V, Croft SL, Ghandehari H: N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers for targeted delivery of 8-aminoquinoline antileishmanial drugs. J. Control. Rel.94,115–127 (2001).
  Google Scholar
• 108  Nan A, Croft SL, Yardley V, Ghandehari H: Targetable water-soluble polymer–drug conjugates for the treatment of visceral leishmaniasis. J. Control. Rel.94,115–127 (2004).
  Medline CASGoogle Scholar
• 109  Minino AM, Heron MP, Murphy SL, Kochanek KD: Deaths: final data for 2004. Natl Vital. Stat. Rep.55(19),1–119 (2007).
  MedlineGoogle Scholar
• 110  Heine H, Rietschel ET, Ulmer AJ: The biology of endotoxin. Mol. Biotechnol.19(3),279–296 (2001).
  Medline CASGoogle Scholar
• 111  Vincent JL: Drotrecogin α (activated): the treatment for severe sepsis? Expert Opin. Biol. Ther.7(11),1763–1777 (2007).
  Medline CASGoogle Scholar
• 112  Cruz DN, Perazella MA, Bellomo R et al.: Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit. Care11(2),R47 (2007).
  MedlineGoogle Scholar
• 113  Shoji H: Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther. Apher. Dial.7(1),108–114 (2003).
  Medline CASGoogle Scholar
• 114  Vicent MJ, Cascales L, Carbajo RJ, Cortés N, Messeguer A, Pérez-Payá E: Nanoconjugates as intracorporeal neutralizers of bacterial endotoxins. J. Control. Rel.142,277–285 (2010).
  Medline CASGoogle Scholar
• 115  Pasut G, Veronese FM: PEG conjugates in clinical development or use as anticancer agents: an overview. Adv. Drug Deliv. Rev.61(13),1176–1188 (2009).
  Google Scholar
• 116  Rodriguez M, Antunez JA, Taboada C, Seijo B, Torres D: Colon-specific delivery of budesonide from microencapsulated cellulosic cores: evaluation of the efficacy against colonic inflammation in rats. J. Pharm. Pharmacol.53(9),1207–1215 (2001).
  Medline CASGoogle Scholar
• 117  Varshosaz J, Emami J, Tavakoli N et al.: Synthesis and evaluation of dextran-budesonide conjugates as colon specific prodrugs for treatment of ulcerative colitis. Int. J. Pharm.365(1–2),69–76 (2009).
  Medline CASGoogle Scholar
• 118  Keely S, Ryan SM, Haddleton DM et al.: Dexamethasone-pDMAEMA polymeric conjugates reduce inflammatory biomarkers in human intestinal epithelial monolayers. J. Control. Rel.135(1),35–43 (2009).▪ pDMAEMA–dexamethasone was found to offer advantages in mucosal delivery over free dexamethasone being a useful tool for the localized delivery of the hydrophobic compound across the epithelium.
  Medline CASGoogle Scholar
• 119  Henson PM: Dampening inflammation. Nat. Immunol.6,1179–1181 (2005).
  Medline CASGoogle Scholar
• 120  Liu X-M, Miller SC, Wang D: Beyond oncology-Application of HPMA copolymers in non-cancerous diseases. Adv. Drug Deliv. Rev.62,258–271 (2010).
  Medline CASGoogle Scholar
• 121  Wang D, Miller SC, Liu XM, Anderson B, Wang XS, Goldring SR: Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis. Arthritis Res. Ther.9(1),R2 (2007).
  MedlineGoogle Scholar
• 122  Hwang J, Rodgers K, Oliver JC, Schluep T: α-methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy. Int. J. Nanomed.3(3),359–371 (2008).
  Medline CASGoogle Scholar
• 123  Kurtoglu YE, Navath RS, Wang B, Kannan S, Romero R, Kannan RM: Poly(amidoamine) dendrimer-drug conjugates with disulfide linkages for intracellular drug delivery. Biomaterials30(11),2112–2121 (2009).
  Medline CASGoogle Scholar
• 124  Hardwicke J, Ferguson EL, Moseley R, Stephens P, Thomas DW, Duncan R: Dextrin-rhEGF conjugates as bioresponsive nanomedicines for wound repair. J. Control. Rel.130(3),275–283 (2008).
  Medline CASGoogle Scholar
• 125  Vicent MJ, Perez-Paya E: Poly-L-glutamic acid (PGA) aided inhibitors of apoptotic protease activating factor 1 (Apaf-1): an antiapoptotic polymeric nanomedicine. J. Med. Chem.49(13),3763–3765 (2006).▪▪ Key paper describing the first polymer antiapoptotic conjugate.
  Medline CASGoogle Scholar
• 126  Shaunak S, Thomas S, Gianasi E et al.: Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat. Biotechnol.22(8),977–984 (2004).
  Medline CASGoogle Scholar
• 127  Fisher M: The ischemic penumbra: identification, evolution and treatment conecpts. Cerebrovasc. Dis.17(Suppl. 1),1–6 (2004).
  MedlineGoogle Scholar
• 128  Bertuglia S, Giusti A: Microvascular oxygenation, oxidative stress, NO suppression and superoxide dismutase during postischemic reperfusion. Am. J. Physiol. Heart Circ. Physiol.285(3),H1064–H1071 (2003).
  Medline CASGoogle Scholar
• 129  Mondragon L, Orzaez M, Sanclimens G et al.: Modulation of cellular apoptosis with apoptotic protease-activating factor 1 (Apaf-1) inhibitors. J. Med. Chem.51(3),521–529 (2008).
  Medline CASGoogle Scholar
• 130  Vicent MJ, Mondragón L, Orzáez M et al.: Polymer-drug conjugates as inhibitors of cellular apoptosis. AAPS J.35,230 (2008).
  Google Scholar
• 131  Goicoechea I, Peri L, Vicent MJ et al.: Evaluation of apoptosis inhibition using Apaf-1 inhibitors (peptoid 1) in an ischaemia-reperfusion Wistar rat model. Eur. Urol.8(Suppl. 4),144 (2009).
  Google Scholar
• 132  Koh KK: Effects of hormone replacement therapy on coagulation and fibrinolysis in postmenopausal women. Int. J. Hematol.76(Suppl. 2),44–46 (2002).
  MedlineGoogle Scholar
• 133  Di Bitondo R, Hall AJ, Peake IR, Iacoviello L, Winship PR: Oestrogenic repression of human coagulation factor VII expression mediated through an oestrogen response element sequence motif in the promoter region. Hum. Mol. Genet.11(7),723–731 (2002).
  Medline CASGoogle Scholar
• 134  Rodriguez-Hernandez A, Rubio-Gayosso I, Ramirez I et al.: Intraluminal-restricted 17 β-estradiol exerts the same myocardial protection against ischemia/reperfusion injury in vivo as free 17 β-estradiol. Steroids73(5),528–538 (2008).
  Medline CASGoogle Scholar
• 135  Bertuglia S, Veronese FM, Pasut G: Polyethylene glycol and a novel developed polyethylene glycol-nitric oxide normalize arteriolar response and oxidative stress in ischemia–reperfusion. Am. J. Physiol. Heart Circ. Physiol.291(4),H1536–H1544 (2006).
  Medline CASGoogle Scholar
• 136  Wang D, Miller SC, Kopeckova P, Kopecek J: Bone-targeting macromolecular therapeutics. Adv. Drug Deliv. Rev.57(7),1049–1076 (2005).
  Medline CASGoogle Scholar
• 137  Lindsay R: Hormones and bone health in postmenopausal women. Endocrine24(3),223–230 (2004).
  Medline CASGoogle Scholar
• 138  Pan H, Liu J, Dong Y et al.: Release of prostaglandin E(1) from N-(2-hydroxypropyl)methacrylamide copolymer conjugates by bone cells. Macromol. Biosci.8(7),599–605 (2008).
  Medline CASGoogle Scholar
• 139  Pan H, Sima M, Kopeckova P et al.: Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates. Mol. Pharm.5(4),548–558 (2008).
  Medline CASGoogle Scholar
• 140  Wang D, Miller S, Sima M, Kopecková P, Kopecek J: Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. Bioconjug. Chem.14,853–859 (2003).
  Medline CASGoogle Scholar
• 141  Greco F, Vicent MJ: Polymer conjugates based combinations for improved treatment of cancer. Adv. Drug Deliv. Rev.61(13),1203–1213 (2009).
  Medline CASGoogle Scholar
• 142  Eskens F, Verweij J: The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors. A review. Eur. J. Cancer42(18),3127–3139 (2006).
  Medline CASGoogle Scholar
• 143  Rowinsky EK, Rizzo J, Ochoa L et al.: A Phase I and pharmacokinetic study of PEGylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J. Clin. Oncol.21(1),148–157 (2003).
  Medline CASGoogle Scholar
• 201  Cerulean Nanopharmaceuticals www.ceruleanrx.com/scienceNanopharmaceuticals.html
  Google Scholar
• 202  Nektar: NXTR-102 www.nektar.com/product_pipeline/oncology_nktr-102.html
  Google Scholar
• 203  CTI. Clinical development: OPAXIO™ www.celltherapeutics.com/opaxio
  Google Scholar
• 204  Nektar: NXTR-105 www.nektar.com/product_pipeline/oncology_nktr-105.html
  Google Scholar
• 205  SynDevRx™, Inc. Synergistic drug development www.syndevrx.com
  Google Scholar
• 206  Nectar: Oral NKTR-118 and Oral NKTR-119 www.nektar.com/product_pipeline/cns_pain_oral_nktr-118and119.html
  Google Scholar